ClinicalTrials.gg
CompletedNCT02663999Updated Jun 13, 2016

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

A Phase 1 interventional study of diazepam nasal spray in Healthy, sponsored by Acorda Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-13.

Sponsored by Acorda Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-center, two-period, randomized, open-label, crossover pharmacokinetic (PK) study in healthy adult volunteers to evaluate dose proportionality of diazepam nasal spray using two dose levels

02

Conditions studied

  • Healthy

Keywords

  • dose proportionality
  • diazepam nasal spray
03

In context

Lead sponsor

Acorda Therapeutics is the lead sponsor of 38 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening body weight 88 to 111 kg, inclusive;
  • General good health with no abnormalities that would affect ability to complete study as determined by medical history, physical examination, visual evaluation of the septum and turbinates to document baseline anatomy, , clinical laboratory test results;
  • Negative drug and alcohol testing;
  • Negative pregnancy test for female subjects of .

Exclusion criteria

Exclusion Criteria:

  • Subject who is not surgically sterile or female subject who is less than 2 years , and who does not agree to use a highly effective method during the study and up to 3 months after the last dose of product;
  • In the judgment of the Investigator, any abnormality (such as septal perforations) or illness that would interfere with participation in this study as determined by medical history, physical examination (including visual exam of septum and turbinates), , clinical laboratory results, or other screening safety tests;
  • Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    diazepam nasal spray (AB)

    Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).

    Drug: diazepam nasal spray

  • Experimental
    diazepam nasal spray (BA)

    Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).

    Drug: diazepam nasal spray

Interventions

  • diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.

    Also known as: PLUMIAZ™ (diazepam) Nasal Spray

06

What researchers measure

Primary outcomes

  1. Maximum measured plasma concentration (Cmax)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

  2. Area under the concentration curve from time 0 to the concentration at 24 hours (AUC0-24)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

  3. Area under the concentration curve from time 0 to infinity (AUCinf)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

  4. Apparent total body clearance of drug from plasma (CL/F)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

Secondary outcomes

  1. Number of patients with adverse events (AEs) including serious AEs

    Time frame: up to 21 days

  2. Change in focused nasal exam

    Time frame: within 30 minutes prior to dosing and at specified time points up to 24 hours post-dose

  3. Taste change questionnaire

    If patient reports a change in taste associated with diazepam nasal spray, questionnaire to be completed by research staff.

    Time frame: from 5 minutes up to 24 hours post-dose

07

Study locations

1 site
  • Site #001
    Dallas, Texas 75247, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Apr 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2016
First posted
Jan 26, 2016
Start
Jan 2016
Primary completionActual
Apr 2016
CompletionActual
Jun 2016
Last update
Jun 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02663999
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Jan 2016
Primary completion
Apr 2016
Completion
Jun 2016
Last update
Jun 13, 2016

Study contacts

David Squillacote, MD
study director · Acorda Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion